Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo

• Main Authors: Zi'ang Xie (Author), Guanxiong Liu (Author), Pan Tang (Author), Xuewu Sun (Author), Shuai Chen (Author), An Qin (Author), Peizhi Zhu (Author), Jianfeng Zhang (Author), Shunwu Fan (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Rheumatoid arthritis (RA), a disease that causes joint destruction and bone erosion, is related to osteoclast activity. RA is generally treated with methotrexate (MTX). In this study, a MTX-Alendronate (ALN) conjugate was synthesized and characterized. The conjugate dramatically inhibited osteoclast...